What is Apotex’s ruxolitinib ANDA status in the U.S.?
I can’t determine the current status from the information provided here. “Status” can mean different things (FDA filing acceptance, whether there’s been an approval, whether there’s a tentative approval, or where it stands in patent litigation), and those specifics require up-to-date FDA/Orange Book or litigation data.
How can I check the real-time status (approval vs. pending) for an ANDA?
To find the latest U.S. status, the most reliable places are:
- FDA’s Orange Book entry for the brand/reference product (to see whether an ANDA applicant is listed and whether it has an approval/tentative approval).
- FDA’s ANDA approval databases (for whether an approval has occurred).
- Court/patent litigation records tied to the brand/reference drug (because ANDA outcomes for ruxolitinib often hinge on patent carve-outs, stays, and 30-month stay timelines, where applicable).
Which ruxolitinib product does Apotex’s ANDA relate to?
“Ruxolitinib” in the U.S. is closely associated with Jakafi (rufolitinib). To confirm which ANDA corresponds to Apotex’s application, you need the:
- Reference listed drug (RLD) name and strength/form (tablet strength and dosing form)
- ANDA applicant name listed in FDA systems (sometimes spelling/parent company names vary)
What details would you need for me to answer precisely?
If you share any one of the following, I can interpret it and tell you what it implies about status:
- the ANDA number for Apotex’s application, or
- the Orange Book listing link/entry text you’re looking at, or
- the brand name it references (e.g., Jakafi) plus the strength/form, or
- the latest FDA action/date shown on a public record you found
Why “status” may be delayed even if an ANDA is accepted
Even when an ANDA is accepted, U.S. launch can be delayed by:
- patent protections listed in the Orange Book,
- FDA-required “180-day exclusivity” triggers (if applicable),
- litigation involving the listed patents,
- 30-month stay or related procedural pauses tied to Hatch-Waxman processes.
If you paste the ANDA number or the Orange Book snippet/link, I’ll map it to the exact stage (pending, tentative approval, approved, stayed) and summarize what that means for U.S. availability.